Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Salt-inducible kinases (SIK) inhibition reduces RANKL-induced osteoclastogenesis.

Lombardi MS, Gilliéron C, Berkelaar M, Gabay C.

PLoS One. 2017 Oct 3;12(10):e0185426. doi: 10.1371/journal.pone.0185426. eCollection 2017.

2.

SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype.

Lombardi MS, Gilliéron C, Dietrich D, Gabay C.

J Leukoc Biol. 2016 May;99(5):711-21. doi: 10.1189/jlb.2A0715-307R. Epub 2015 Nov 20.

PMID:
26590148
3.

A thematic analysis of delusion with religious contents in schizophrenia: open, closed, and mixed dynamics.

Rieben I, Mohr S, Borras L, Gillieron C, Brandt PY, Perroud N, Huguelet P.

J Nerv Ment Dis. 2013 Aug;201(8):665-73. doi: 10.1097/NMD.0b013e31829c5073.

PMID:
23896847
4.

Spirituality and religion in outpatients with schizophrenia: a multi-site comparative study of Switzerland, Canada, and the United States.

Mohr S, Borras L, Nolan J, Gillieron C, Brandt PY, Eytan A, Leclerc C, Perroud N, Whetten K, Pieper C, Koenig HG, Huguelet P.

Int J Psychiatry Med. 2012;44(1):29-52.

PMID:
23356092
5.

A randomized trial of spiritual assessment of outpatients with schizophrenia: patients' and clinicians' experience.

Huguelet P, Mohr S, Betrisey C, Borras L, Gillieron C, Marie AM, Rieben I, Perroud N, Brandt PY.

Psychiatr Serv. 2011 Jan;62(1):79-86. doi: 10.1176/ps.62.1.pss6201_0079.

PMID:
21209304
6.

Spirituality and religiousness as predictive factors of outcome in schizophrenia and schizo-affective disorders.

Mohr S, Perroud N, Gillieron C, Brandt PY, Rieben I, Borras L, Huguelet P.

Psychiatry Res. 2011 Apr 30;186(2-3):177-82. doi: 10.1016/j.psychres.2010.08.012. Epub 2010 Sep 24.

PMID:
20869123
7.

Delusions with religious content in patients with psychosis: how they interact with spiritual coping.

Mohr S, Borras L, Betrisey C, Pierre-Yves B, Gilliéron C, Huguelet P.

Psychiatry. 2010 Summer;73(2):158-72. doi: 10.1521/psyc.2010.73.2.158.

PMID:
20557227
8.

Religious explanatory models in patients with psychosis: a three-year follow-up study.

Huguelet P, Mohr S, Gilliéron C, Brandt PY, Borras L.

Psychopathology. 2010;43(4):230-9. doi: 10.1159/000313521. Epub 2010 Apr 28.

PMID:
20424504
9.

Evolution of spirituality and religiousness in chronic schizophrenia or schizo-affective disorders: a 3-years follow-up study.

Mohr S, Borras L, Rieben I, Betrisey C, Gillieron C, Brandt PY, Perroud N, Huguelet P.

Soc Psychiatry Psychiatr Epidemiol. 2010 Nov;45(11):1095-103. doi: 10.1007/s00127-009-0151-0. Epub 2009 Oct 11.

PMID:
19821066
10.

Religion and spirituality: how clinicians in quebec and geneva cope with the issue when faced with patients suffering from chronic psychosis.

Borras L, Mohr S, Gillieron C, Brandt PY, Rieben I, Leclerc C, Huguelet P.

Community Ment Health J. 2010 Feb;46(1):77-86. doi: 10.1007/s10597-009-9247-y. Epub 2009 Sep 22.

PMID:
19771517
11.

GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.

Gobert RP, van den Eijnden M, Szyndralewiez C, Jorand-Lebrun C, Swinnen D, Chen L, Gillieron C, Pixley F, Juillard P, Gerber P, Johnson-Léger C, Halazy S, Camps M, Bombrun A, Shipp M, Vitte PA, Ardissone V, Ferrandi C, Perrin D, Rommel C, Hooft van Huijsduijnen R.

J Biol Chem. 2009 Apr 24;284(17):11385-95. doi: 10.1074/jbc.M807241200. Epub 2009 Feb 20.

12.

Influence of spirituality and religiousness on substance misuse in patients with schizophrenia or schizo-affective disorder.

Huguelet P, Borras L, Gillieron C, Brandt PY, Mohr S.

Subst Use Misuse. 2009;44(4):502-13. doi: 10.1080/10826080802344872.

PMID:
19219658
13.

Influence of spirituality and religiousness on smoking among patients with schizophrenia or schizo-affective disorder in Switzerland.

Borras L, Mohr S, Brandt PY, Gillieron C, Eytan A, Huguelet P.

Int J Soc Psychiatry. 2008 Nov;54(6):539-49. doi: 10.1177/0020764008091424.

PMID:
18974192
14.

The assessment of spirituality and religiousness in schizophrenia.

Mohr S, Gillieron C, Borras L, Brandt PY, Huguelet P.

J Nerv Ment Dis. 2007 Mar;195(3):247-53.

PMID:
17468685
15.

Structure of the naphthalene dimer from rare gas tagging.

Gilliéron C, Sharma N, Nauta K, Schmidt TW.

J Phys Chem A. 2007 May 24;111(20):4211-4. Epub 2007 Apr 21.

PMID:
17447737
16.

Religious beliefs in schizophrenia: their relevance for adherence to treatment.

Borras L, Mohr S, Brandt PY, Gilliéron C, Eytan A, Huguelet P.

Schizophr Bull. 2007 Sep;33(5):1238-46. Epub 2007 Jan 9.

17.

Effect of religion on suicide attempts in outpatients with schizophrenia or schizo-affective disorders compared with inpatients with non-psychotic disorders.

Huguelet P, Mohr S, Jung V, Gillieron C, Brandt PY, Borras L.

Eur Psychiatry. 2007 Apr;22(3):188-94. Epub 2006 Nov 30.

PMID:
17140770
18.

Toward an integration of spirituality and religiousness into the psychosocial dimension of schizophrenia.

Mohr S, Brandt PY, Borras L, Gilliéron C, Huguelet P.

Am J Psychiatry. 2006 Nov;163(11):1952-9.

PMID:
17074947
19.

[Spirituality, religious practices and schizophrenia: relevance for the clinician].

Mohr S, Borras L, Gillieron C, Brandt PY, Huguelet P.

Rev Med Suisse. 2006 Sep 20;2(79):2092-4, 2096-8. French.

PMID:
17073175
20.

Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.

Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C, Gillieron C, Françon B, Perrin D, Leroy D, Gretener D, Nichols A, Vitte PA, Carboni S, Rommel C, Schwarz MK, Rückle T.

J Med Chem. 2006 Jun 29;49(13):3857-71.

PMID:
16789742
21.

Spirituality and religious practices among outpatients with schizophrenia and their clinicians.

Huguelet P, Mohr S, Borras L, Gillieron C, Brandt PY.

Psychiatr Serv. 2006 Mar;57(3):366-72.

PMID:
16524995
22.

Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1.

Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, Grumont RJ, Gillieron C, Mackay F, Grey S, Camps M, Rommel C, Gerondakis SD, Mackay CR.

Nat Immunol. 2006 Mar;7(3):274-83. Epub 2006 Feb 12.

PMID:
16474395
23.

Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.

Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Françon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C.

Nat Med. 2005 Sep;11(9):936-43. Epub 2005 Aug 28.

24.

Involvement of phosphoinositide 3-kinase gamma, Rac, and PAK signaling in chemokine-induced macrophage migration.

Weiss-Haljiti C, Pasquali C, Ji H, Gillieron C, Chabert C, Curchod ML, Hirsch E, Ridley AJ, Hooft van Huijsduijnen R, Camps M, Rommel C.

J Biol Chem. 2004 Oct 8;279(41):43273-84. Epub 2004 Jul 29.

25.

MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2alpha.

Castelli M, Camps M, Gillieron C, Leroy D, Arkinstall S, Rommel C, Nichols A.

J Biol Chem. 2004 Oct 22;279(43):44731-9. Epub 2004 Jul 28.

26.

c-Jun N-terminal kinase-3 (JNK3)/stress-activated protein kinase-beta (SAPKbeta) binds and phosphorylates the neuronal microtubule regulator SCG10.

Neidhart S, Antonsson B, Gilliéron C, Vilbois F, Grenningloh G, Arkinstall S.

FEBS Lett. 2001 Nov 16;508(2):259-64.

27.

Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3.

Nichols A, Camps M, Gillieron C, Chabert C, Brunet A, Wilsbacher J, Cobb M, Pouyssegur J, Shaw JP, Arkinstall S.

J Biol Chem. 2000 Aug 11;275(32):24613-21.

28.

MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases.

Theodosiou A, Smith A, Gillieron C, Arkinstall S, Ashworth A.

Oncogene. 1999 Nov 25;18(50):6981-8.

29.

Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase.

Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, Chabert C, Boschert U, Arkinstall S.

Science. 1998 May 22;280(5367):1262-5.

30.

The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity.

Muda M, Theodosiou A, Gillieron C, Smith A, Chabert C, Camps M, Boschert U, Rodrigues N, Davies K, Ashworth A, Arkinstall S.

J Biol Chem. 1998 Apr 10;273(15):9323-9.

31.

Induction of the mitogen-activated protein kinase phosphatase MKP3 by nerve growth factor in differentiating PC12.

Camps M, Chabert C, Muda M, Boschert U, Gillieron C, Arkinstall S.

FEBS Lett. 1998 Mar 27;425(2):271-6.

33.

Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1.

Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinou JC, Arkinstall S.

J Biol Chem. 1997 Oct 3;272(40):25238-42.

34.

Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4.

Muda M, Boschert U, Smith A, Antonsson B, Gillieron C, Chabert C, Camps M, Martinou I, Ashworth A, Arkinstall S.

J Biol Chem. 1997 Feb 21;272(8):5141-51.

35.

The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases.

Muda M, Theodosiou A, Rodrigues N, Boschert U, Camps M, Gillieron C, Davies K, Ashworth A, Arkinstall S.

J Biol Chem. 1996 Nov 1;271(44):27205-8.

Supplemental Content

Loading ...
Support Center